Alterity Therapeutics (NASDAQ:ATHE) Now Covered by Analysts at JonesTrading

Stock analysts at JonesTrading initiated coverage on shares of Alterity Therapeutics (NASDAQ:ATHE) in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage set a “buy” rating and a $16.00 price target on the stock. JonesTrading’s price objective would indicate a potential upside of 216.71% from the company’s previous close.

Other analysts also recently issued research reports about the company. LADENBURG THALM/SH SH initiated coverage on Alterity Therapeutics in a research note on Tuesday, June 16th. They set a “buy” rating and a $10.00 target price for the company. Zacks Research raised shares of Alterity Therapeutics to a “hold” rating in a research report on Wednesday, June 17th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Alterity Therapeutics in a research note on Monday, April 20th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Alterity Therapeutics has an average rating of “Hold” and an average price target of $13.00.

Alterity Therapeutics Stock Performance

Shares of ATHE opened at $5.05 on Tuesday. Alterity Therapeutics has a 12 month low of $4.14 and a 12 month high of $350.00. The company’s fifty day moving average is $4.47 and its 200-day moving average is $3.76.

Institutional Trading of Alterity Therapeutics

An institutional investor recently bought a new stake in Alterity Therapeutics stock. Citadel Advisors LLC bought a new stake in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 22,144 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned about 0.25% of Alterity Therapeutics as of its most recent filing with the SEC. 2.14% of the stock is currently owned by institutional investors and hedge funds.

Alterity Therapeutics Company Profile

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.